Detail akcie Utd Therapeut online

Business Summary: United Therapeutics Corporation is a pharmaceutical company. It markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection (Unituxin) for treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin (Remunity). Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder.
Financial Summary: BRIEF: For the three months ended 31 March 2024, United Therapeutics Corporation revenues increased 34% to $677.7M. Net income increased 27% to $306.6M. Revenues reflect Orenitram segment increase of 20% to $106.2M, Unituxin segment increase of 19% to $58.4M, United States segment increase of 37% to $641.5M. Net income was partially offset by Share-based compensation increase from $13.3M (income) to $18.1M (expense), Selling.